MNMD Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol QF:NMED.

$1.86  -0.13 (-6.53%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  11/15/2016
Outstanding shares:  453,755,670
Average volume:  4,514,927
Market cap:   $902,973,783
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    60255C109
ISIN:        CA60255C1095
Sedol:      BLLZL07
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.70
PS ratio:   0.00
Return on equity:   -53.12%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy